Do you routinely offer PARP inhibitor maintenance therapy to germline BRCA1/2+, FIGO stage II serous ovarian carcinoma patients after adjuvant chemotherapy?

We are not offering PARPi maintenance in early stage disease at this time. We are in line with the data showing benefit in advanced stage disease. While the data are compelling, you must remember that that these medications 1) have side effects including risk of MDS and 2) can be used in the recurre...